Barclays lowered the firm’s price target on Ultragenyx (RARE) to $44 from $50 and keeps an Overweight rating on the shares after the company announced that neither of the Phase 3 Orbit and Cosmic studies for setrusumab in osteogenesis imperfecta achieved statistical significance against their primary endpoints.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx: Refocusing on Apazunersen and Strengthened Balance Sheet Support Buy Rating Despite OI Setback
- Truist says focus now on Apazunersen after Ultragenyx’s Setrusumab miss
- Ultragenyx price target lowered to $50 from $103 at Citi
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Ultragenyx price target lowered to $84 from $105 at Cantor Fitzgerald